Should Chief Justice Recuse in Landmark ‘Wyeth’ Case?
One of the top cases of the current Supreme Court term is , asking whether a state law tort action challenging the
labeling on a Wyeth drug is pre-empted by federal law. Now, the outcome
of the case could be in question because of the recent announcement by
Pfizer Inc. that it would acquire Wyeth. Chief Justice John Roberts
Jr.’s ownership of Pfizer stock has prompted his recusal in previous
cases. The decision in the case is likely to affect Wyeth’s value, and,
in turn, Pfizer’s.
Comments(0)